• March 7, 2025 Announcement of Licensing Agreement with Brill International（PDF）
• February 20, 2025 Launch and Distribution of “MIEr for BeelineMED”（PDF）
• January 17, 2025 Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132（PDF）
• November 26, 2024 Launch and Distribution of “MIEr for ImageFS”（PDF）
• September 6, 2024 Launch of Distribution of Software for Dry-eye Analysis（PDF）
• September 3, 2024 Acquisition of Marketing Approval for “ Mytear LUMIFY”（PDF）
• July 26, 2024 Launch of Distribution of RET-700（PDF）
• July 16, 2024 Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132（PDF）
• July 8, 2024 Notice of Orphan Drug Designation for SJP-0008 as a Treatment of Central Retinal Artery Occlusion（PDF）
• May 9, 2024 Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion（PDF）
• April 23, 2024 Launch and Distribution of “MIEr for NAVIS”（PDF）
• November 1, 2023 Launch of Distribution of the OptiLight M22 IPL Model（PDF）
• September 7, 2023 Launch of Distribution of “Smart MIEr”（PDF）

More